Skip to main content

Advertisement

SpringerLink
Log in

Novel therapeutic strategies in scleroderma

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Optimal management for scleroderma (systemic sclerosis) is likely to require treatment of the underlying disease process, which remains incompletely understood, and also of the organ-based complications of this heterogeneous condition. Clinical trials evaluating several potential agents have been completed recently, including D-penicillamine and interferon alpha. Unfortunately none of these studies has suggested significant efficacy. This article focuses on new treatment approaches using existing therapeutic agents, such as prostacyclin, and considers the potential usefulness of new agents (eg, relaxin, halofuginone) or strategies such as intensive immunosuppression with peripheral stem cell rescue. Ultimately, a better understanding of disease pathogenesis may facilitate the development of targeted therapy against key events or mediators, but for the present better evaluation of existing agents and a focus on optimizing protocols for organ-based complications, such as pulmonary vascular disease or hypertensive renal crisis, are important goals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rose NR, Leskovsek N: Scleroderma: immunopathogenesis and treatment. Immunol Today 1998, 19:499–501.

    Article  PubMed  CAS  Google Scholar 

  2. Silman AJ: Scleroderma-demographics and survival. J Rheumatol Suppl 1997, 48:58–61.

    PubMed  CAS  Google Scholar 

  3. Black CM, Silman AJ, Herrick A, et al.: Alpha interferon does not improve outcome at one year in patients with diffuse cutaneous scleroderma. Arthritis Rheum 1999, 42:299–305. Another negative study for an agent previously in clinical use for scleroderma. The overall conclusion was that Interferon A is of no value in the treatment of scleroderma and may in fact be deleterious.

    Article  PubMed  CAS  Google Scholar 

  4. Clements PJ, Wong WK, Seibold JR, et al.: High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: Analysis of trial. Arthritis Rheum 1997, 40:S854. One of the most rigorously controlled interventional studies in scleroderma performed to date. Unfortunately the overall finding was that conventional dose D-penicillamine was no more effective than a very low dose, implying a lack of efficacy for the high-dose regimen.

    Article  Google Scholar 

  5. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al.:Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24-week randomized, double-blind trial, followed by a 24-week observational trial. Arthritis Rheum 1998, 40:S.

    Google Scholar 

  6. Furst DE, Clements PJ, Hillis S, et al.: Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989, 32:584–593.

    Article  PubMed  CAS  Google Scholar 

  7. White B, Bauer EA, Goldsmith LA, et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). I.Diseasemodifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995, 38:351–360. The first set of published guidelines should help to improve and standardize interventional studies in scleroderma.

    Article  PubMed  CAS  Google Scholar 

  8. Pope JE, Bellamy N: Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. Clin Invest Med 1995, 18:1–10.

    PubMed  CAS  Google Scholar 

  9. Amlot P, Bacon P, Belch JJF, et al.: How can treatment of systemic sclerosis be improved? By setting up a national database of all cases and entering patients into trials. Br Med J 1998, 317:294–295.

    Google Scholar 

  10. Mayes MD, Giannini EH, Pachman LM, et al.: Connective tissue disease registries. Arthritis Rheum 1997, 40:1556–1559.

    Article  PubMed  CAS  Google Scholar 

  11. Ceru S, Pancera P, Sansone S, et al.: Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 1997, 15:381–385.

    PubMed  CAS  Google Scholar 

  12. Scorza R, Rivolta R, Mascagni B, et al.: Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997, 24:1944–1948.

    PubMed  CAS  Google Scholar 

  13. MacGregor AJ, Davrashvili J, Knight C, et al.: Early Pulmonary Hypertension in Systemic Sclerosis: Risk of Progression and Consequences for Survival. Arthritis Rheum 1996, 39:S46.

    Google Scholar 

  14. Menon N, Menon N, McAlpine L, et al.: The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis Rheum 1998; 41:466–469.

    Article  PubMed  CAS  Google Scholar 

  15. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296–301. A landmark study demonstrating substantial benefit from ambulatory continuous prostacyclin for patients with primary pulmonary hypertension that may well be extrapolated to pulmonary hypertension complicating scleroderma.

    Article  PubMed  CAS  Google Scholar 

  16. Higenbottam T, Butt AY, McMahon A, et al.: Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998, 80:151–155.

    PubMed  CAS  Google Scholar 

  17. Gaine SP, Rubin LJ: Primary pulmonary hypertension. Lancet 1998, 352:719–725.

    Article  PubMed  CAS  Google Scholar 

  18. Badesch DB, Brindage BH, McGoon MD, et al.: Continuous intravenous epoprostaol versus conventional therapy in pulmonary hypertension due to the scleroderma spectrum of diseases: A 12-week multicenter randomised controlled trial. Circulation 1998, 98:S614.

    Google Scholar 

  19. De la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ: Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994, 37:1528–1533.

    Article  PubMed  Google Scholar 

  20. Bartosik I, Eskilsson J, Scheja A, Akesson A: Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma—a pilot study. Br J Rheumatol 1996, 35:1187–8.

    Article  PubMed  CAS  Google Scholar 

  21. Mikhail G, Gibbs J, Richardson M, et al.: An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997, 18:1499–1504.

    PubMed  CAS  Google Scholar 

  22. Belch JJ, Capell HA, Cooke ED, et al.: Oral iloprost as a treatment for Raynaud’s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995, 54:197–200.

    Article  PubMed  CAS  Google Scholar 

  23. Black CM, Halkier-Sorensen L, Belch JJ, et al.: Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998; 37:952–960.

    Article  PubMed  CAS  Google Scholar 

  24. Wigley FM, Korn JH, Csuka ME, et al.: Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998, 41:670–677.

    Article  PubMed  CAS  Google Scholar 

  25. Hafner J, Della Santa D, Zuber C, et al.: Digital sympathectomy (microarteriolysis) in the treatment of severe Raynaud’s phenomenon secondary to systemic sclerosis. Br J Dermatol 1997, 137:1019–1020.

    PubMed  CAS  Google Scholar 

  26. Stratton R, Howell K, Goddard N, Black C: Digital sympathectomy for ischaemia in scleroderma. Br J Rheumatol 1997, 36:1338–1339.

    Article  PubMed  CAS  Google Scholar 

  27. Clements PJ, Furst DE: Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. J Rheumatol Suppl 1997, 48:85–88. Guidelines for patients in North America who are to be treated by immunosuppression and peripheral stem-cell rescue.

    PubMed  CAS  Google Scholar 

  28. Tyndall A, Gratwohl A: Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997, 36:390–392. Guidelines for patients in Europe who are to be treated by immunosuppression and peripheral stem-cell rescue.

    Article  PubMed  CAS  Google Scholar 

  29. Brooks PM: Hematopoietic stem cell transplantation for autoimmune diseases. J Rheumatol Suppl 1997, 48:19–22.

    PubMed  CAS  Google Scholar 

  30. Burt RK, Traynor AE, Pope R, et al.: Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998, 92:3505–3514.

    PubMed  CAS  Google Scholar 

  31. Brodsky RA, Petri M, Smith BD, et al.: Immunoablative highdose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998, 129:1031–1035.

    PubMed  CAS  Google Scholar 

  32. Tyndall A, Black C, Finke J, et al.: Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997, 349:254.

    Article  PubMed  CAS  Google Scholar 

  33. Furst DE, McSweeney P, Nelson JL, et al.: Intensive immunosuppression and stem cell transplantation in scleroderma. Arthritis Rheum 1998, 40:S416.

    Google Scholar 

  34. Halevy O, Nagler A, Levi-Schaffer F, et al.: Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996, 52:1057–1063.

    Article  PubMed  CAS  Google Scholar 

  35. Pines M, Nagler A: Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998, 30:445–450.

    Article  PubMed  CAS  Google Scholar 

  36. Levi-Schaffer F, Nagler A, Slavin S, et al.: Inhibition of collagen synthesis and changes in skin morphology in murine graftversus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 1996, 106:84–88. Promising animal data demonstrate that the plant alkaloid halofuginone has potential as a novel antifibrotic therapy.

    Article  PubMed  CAS  Google Scholar 

  37. Unemori EN, Bauer EA, Amento EP: Relaxin alone and in conjunction with interferon-gamma decreases collagen synthesis by cultured human scleroderma fibroblasts. J Invest Dermatol 1992; 99:337–342.

    Article  PubMed  CAS  Google Scholar 

  38. Seibold JR, Clements PJ, Furst DE, et al.: Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol 1998; 25:302–307. Encouraging, if preliminary, findings suggesting that parenteral administration of recombinant human relaxin may be beneficial for scleroderma.

    PubMed  CAS  Google Scholar 

  39. Marczin N, Riedel B, Royston D, Yacoub M: Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis. Lancet 1998, 352:405–406.

    Article  PubMed  CAS  Google Scholar 

  40. Rolla G, Colagrande P, Brussino L, et al.: Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. Lancet 1998, 351:1491–1492.

    Article  PubMed  CAS  Google Scholar 

  41. Ramsay MA, Spikes C, East CA, et al.: The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999, 90:299–301.

    Article  PubMed  CAS  Google Scholar 

  42. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M: Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998, 32:1068–1073.

    Article  PubMed  CAS  Google Scholar 

  43. Parsons S, Celermajer D, Savidis E, et al.: The effect of inhaled nitric oxide on 6-minute walk distance in patients with pulmonary hypertension. Chest 1998, 114:70S-72S.

    PubMed  CAS  Google Scholar 

  44. McKown KM, Carbone LD, Bustillo J, et al.: Open trial of oral type I collagen in patients with systemic sclerosis. Arthritis Rheum 1997, 40:S418.

    Google Scholar 

  45. Le CH, Morales A, Trentham DE: Minocycline in early diffuse scleroderma. Lancet 1998, 352:1755–1756.

    Article  PubMed  CAS  Google Scholar 

  46. Denton CP, Bunce T, Howell K, et al.: Probucol treatment improves symptoms and reduced lipoprotein oxidation susceptibility in Raynaud’s phenomenon. Rheumatology 1999, in press.

  47. Denton CP, Black CM, Korn JH, de Crombrugghe B: Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996, 347:1453–1458.

    Article  Google Scholar 

  48. Medsger TA, Silman AJ, Steen VD: Development of a severity index for systemic sclerosis. Arthritis Rheum 1994, 37:S260.

    Google Scholar 

  49. Herrick AL, Rieley F, Schofield D, et al.: Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 1994, 21:1477–1483.

    PubMed  CAS  Google Scholar 

  50. Bruckdorfer KR, Hillary JB, Bunce T, et al.: Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995, 38:1060–1067.

    Article  PubMed  CAS  Google Scholar 

  51. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996, 39:1146–50.

    Article  PubMed  CAS  Google Scholar 

  52. Sambo P, Jannino L, Canddella M, et al.: Monocytes of patients with systemic sclerosis spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999, 112:78–84.

    Article  PubMed  CAS  Google Scholar 

  53. Farber JL, Kyle ME, Coleman JB: Mechanisms of cell injury by activated oxygen species. Lab Invest 1990, 62:670–679.

    PubMed  CAS  Google Scholar 

  54. Casciola-Rosen L, Wigley F, Rosen A: Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997, 185:71–79. This paper demonstrates a potential mechanistic link between reactive oxidant stress, heavy metal exposure, and autoantibody formation in scleroderma and provides some rationale for using antioxidant strategies as disease-modifying treatments.

    Article  PubMed  CAS  Google Scholar 

  55. Ong C, Wong C, Roberts CR, et al.: Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol. 1998; 28:2619–2629.

    Article  PubMed  CAS  Google Scholar 

  56. T Ogawa, K Ogawa, E Saito, H Fukuya: Anti-IL1beta monoclonal antibody prevents skin fibrosis in the tight-skin mouse. Arthritis Rheum 1998, 41:S1481.

    Article  Google Scholar 

  57. Denton CP, Shi-wen X, Black CM, Pearson JD: Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. J Invest Dermatol (1997) 108:269–274.

    Article  PubMed  CAS  Google Scholar 

  58. Feghali CA, Bost KL, Boulware DW, Levy LS: (1994) Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994, 17:309–318.

    PubMed  CAS  Google Scholar 

  59. Shi-wen X, Panesar M, Vancheeswaran R, et al.: (1994) Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994, 37:1689–1697.

    Article  PubMed  CAS  Google Scholar 

  60. Hitraya EG, Varga J, Artlett CM, Jimenez SA: Identification of elements in the proximal promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998, 41:2048–2058.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Rheumatology, Royal Free and University College Medical School, Royal Free Campus, London, NW3, UK

    Christopher P. Denton PhD, MRCP & Carol M. Black MD, FRCP

Authors
  1. Christopher P. Denton PhD, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol M. Black MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Denton, C.P., Black, C.M. Novel therapeutic strategies in scleroderma. Curr Rheumatol Rep 1, 22–27 (1999). https://doi.org/10.1007/s11926-999-0020-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-999-0020-6

Keywords

Search

Navigation